Diseases, Free Full-Text

Por um escritor misterioso
Last updated 05 junho 2024
Diseases, Free Full-Text
(1) Introduction: Traumatic brain injury (TBI) is a leading cause of injury and mortality worldwide, carrying an estimated cost of $38 billion in the United States alone. Neutrophil to lymphocyte ratio (NLR) has been investigated as a standardized biomarker that can be used to predict outcomes of TBI. The aim of this review was to determine the prognostic utility of NLR among patients admitted for TBI. (2) Methods: A literature search was conducted in PubMed, Scopus, and Web of Science in November 2022 to retrieve articles regarding the use of neutrophil to lymphocyte ratio (NLR) as a prognostic measure in traumatic brain injury (TBI) patients. Inclusion criteria included studies reporting outcomes of TBI patients with associated NLR values. Exclusion criteria were studies reporting only non-primary data, those insufficiently disaggregated to extract NLR data, and non-English or cadaveric studies. The Newcastle-Ottawa Scale was utilized to assess for the presence of bias in included studies. (3) Results: Following the final study selection 19 articles were included for quantitative and qualitative analysis. The average age was 46.25 years. Of the 7750 patients, 73% were male. Average GCS at presentation was 10.51. There was no significant difference in the NLR between surgical vs. non-surgical cohorts (SMD 2.41 95% CI −1.82 to 6.63, p = 0.264). There was no significant difference in the NLR between bleeding vs. non-bleeding cohorts (SMD 4.84 95% CI −0.26 to 9.93, p = 0.0627). There was a significant increase in the NLR between favorable vs. non-favorable cohorts (SMD 1.31 95% CI 0.33 to 2.29, p = 0.0090). (4) Conclusions: Our study found that NLR was only significantly predictive for adverse outcomes in TBI patients and not surgical treatment or intracranial hemorrhage, making it nonetheless an affordable alternative for physicians to assess patient prognosis.
Diseases, Free Full-Text
Implementation of non-communicable disease policies from 2015 to 2020: a geopolitical analysis of 194 countries - The Lancet Global Health
Diseases, Free Full-Text
Effects of lifelong testosterone exposure on health and disease using Mendelian randomization
Diseases, Free Full-Text
Frontiers Serum/plasma biomarkers and the progression of cardiometabolic multimorbidity: a systematic review and meta-analysis
Diseases, Free Full-Text
Eradication of Diseases - Our World in Data
Diseases, Free Full-Text
Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death
Diseases, Free Full-Text
COVID Resources Maryland Developmental Disabilities Council
Diseases, Free Full-Text
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
Diseases, Free Full-Text
Eradication of Diseases - Our World in Data
Diseases, Free Full-Text
Physical Activity and Nutrition
Diseases, Free Full-Text
Heart Disease: Symptoms & Causes
Diseases, Free Full-Text
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease
[Cohen M Sc FRCP FRCPath FRCPE FMedSci, Jonathan, Powderly MD, William G., Opal MD, Steven M.] on . *FREE* shipping on qualifying
Diseases, Free Full-Text
Infectious Diseases: Expert Consult: Online and Print - 2 Volume Set (INFECTIOUS DISEASES - COHEN (WAS ARMSTRONG))
Diseases, Free Full-Text
What Does it Mean to Have an Asymptomatic Disease?
Diseases, Free Full-Text
Prevalence of access to treatment of chronic diseases in Brazil and

© 2014-2024 khosatthep.net. All rights reserved.